SESN

Sesen BioNasdaqGM:SESN Stock Report

Market Cap

US$183.4m

7D

-4.1%

1Y

-17.2%

Updated

16 Sep, 2021

Data

Company Financials +
SESN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SESN Overview

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.

Share Price & News

How has Sesen Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SESN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: SESN's weekly volatility has increased from 16% to 25% over the past year.


Market Performance


7 Day Return

-4.1%

SESN

-1.0%

US Biotechs

-0.6%

US Market


1 Year Return

-17.2%

SESN

24.9%

US Biotechs

33.7%

US Market

Return vs Industry: SESN underperformed the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: SESN underperformed the US Market which returned 30.7% over the past year.


Shareholder returns

SESNIndustryMarket
7 Day-4.1%-1.0%-0.6%
30 Day-38.0%0.8%1.4%
90 Day-78.5%6.6%5.4%
1 Year-17.2%-17.2%26.5%24.9%35.7%33.7%
3 Year-54.8%-54.8%18.3%12.8%61.2%51.2%
5 Year-70.2%-70.2%46.7%35.2%123.8%99.4%

Long-Term Price Volatility Vs. Market

How volatile is Sesen Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Sesen Bio Fundamentals Summary

How do Sesen Bio's earnings and revenue compare to its market cap?
SESN fundamental statistics
Market CapUS$183.38m
Earnings (TTM)-US$118.86m
Revenue (TTM)US$17.78m

10.3x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SESN income statement (TTM)
RevenueUS$17.78m
Cost of RevenueUS$29.07m
Gross Profit-US$11.29m
ExpensesUS$107.58m
Earnings-US$118.86m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.82
Gross Margin-63.49%
Net Profit Margin-668.53%
Debt/Equity Ratio0%

How did SESN perform over the long term?

See historical performance and comparison

Valuation

Is Sesen Bio undervalued compared to its fair value and its price relative to the market?

3.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SESN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SESN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SESN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: SESN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SESN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SESN is overvalued based on its PB Ratio (3.7x) compared to the US Biotechs industry average (3.1x).


Future Growth

How is Sesen Bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

21.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SESN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SESN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SESN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SESN's revenue (46.7% per year) is forecast to grow faster than the US market (9.5% per year).

High Growth Revenue: SESN's revenue (46.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SESN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Sesen Bio performed over the past 5 years?

-39.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SESN is currently unprofitable.

Growing Profit Margin: SESN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SESN is unprofitable, and losses have increased over the past 5 years at a rate of 39% per year.

Accelerating Growth: Unable to compare SESN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SESN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: SESN has a negative Return on Equity (-240.27%), as it is currently unprofitable.


Financial Health

How is Sesen Bio's financial position?


Financial Position Analysis

Short Term Liabilities: SESN's short term assets ($175.1M) exceed its short term liabilities ($18.8M).

Long Term Liabilities: SESN's short term assets ($175.1M) exceed its long term liabilities ($172.9M).


Debt to Equity History and Analysis

Debt Level: SESN is debt free.

Reducing Debt: SESN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SESN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SESN has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 14.4% each year.


Dividend

What is Sesen Bio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SESN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SESN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SESN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SESN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SESN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Thomas Cannell (59 yo)

3.08yrs

Tenure

US$1,702,506

Compensation

Dr. Thomas R. Cannell, DVM, has been President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD1.70M) is above average for companies of similar size in the US market ($USD1.08M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SESN's management team is considered experienced (2.1 years average tenure).


Board Members

Experienced Board: SESN's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 67.3%.


Top Shareholders

Company Information

Sesen Bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sesen Bio, Inc.
  • Ticker: SESN
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$183.380m
  • Shares outstanding: 196.00m
  • Website: https://www.sesenbio.com

Number of Employees


Location

  • Sesen Bio, Inc.
  • 245 First Street
  • Suite 1800
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Biography

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 04:46
End of Day Share Price2021/09/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.